|
Australia-QLD-YANDARAN Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Cell-free DNA approaches for cancer early detection and . . .
We evaluate progress in the development of early cancer detection tests in the context of the current principles for cancer screening We review cell-free DNA (cfDNA)-based approaches using mutations, methylation, or fragmentomes for early cancer detection
- Ultrasensitive ctDNA detection for preoperative disease . . .
Through an analysis of 171 patients with early-stage lung cancer from the TRACERx study, we detected ctDNA pre-operatively within 81% of patients with lung adenocarcinoma (LUAD), including 53% of
- High-sensitive multi-cancers early detection for 8 cancer . . .
We developed blood-based multi-cancers early detection (MCED) and cancer signal origin (CSO) approaches in 8 types of cancers including esophageal, stomach, colorectal, pancreatic, liver, lung, breast and ovarian cancer Methods: DNA methylation data generated based on GM-seq by public and internal whole genome methylation data
- Ultrasensitive Detection and Monitoring of Circulating Tumor . . .
Purpose: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy in early-stage breast cancer is highly prognostic of disease recurrence Current ctDNA assays, mainly targeting single-nucleotide variants, vary in sensitivity and specificity
- Bisulfite-free detection of DNA methylation in early-stage . . .
This novel method integrates the specific affinity of 5mC antibody for methylated DNA with the multiplexing capabilities and ultra-sensitivity of SERS, enabling the detection of gene-specific DNA methylation without the need for bisulfite treatment or complex nucleic acid amplification processes
- Diagnostic Power of DNA Methylation Classifiers for Early . . .
Current methods for detection of ctDNA are often based on sequencing somatic mutations in cfDNA, which is invaluable for monitoring tumor cell clones with actionable mutations However, the diagnostic sensitivity of these methods may be low among patients with early-stage cancer due to the limited number of recurrent mutations [3, 4]
- The future of early cancer detection - Nature Medicine
Hence, the concept of early cancer detection can include the proactive identification of tissue (including blood) abnormalities that are indicative of a precancerous or in situ stage,
|
|